Skip to main content
Signal8

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Sector: Biotechnology

Industry: Biotechnology

RegeneRx Biopharmaceuticals, Inc. logo

RegeneRx Biopharmaceuticals, Inc.

OTC:RGRXHealthcare
CLOSED
Mkt Cap-
EV-
Float836K
O/S1.5M
VOL251 sh
$ Vol$0
Inst Own-
Net Cash/Sh-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Oct 14, 20260.00110.00110.00110.0011251
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
1
HOLD
0
SELL
0
TOTAL1
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
--
Institutional
(0)
--
Insiderⓘ
(0)
--
5%+ Owners
(0)
--
Unattributed (incl. retail)ⓘ
Sources:
About

RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs.

The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000.

Its operations are headquartered in Rockville, Maryland.

Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO Date-
Shares Outstanding1.50M
Authorized Shares
Float836,250
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

251

90d Avg

377

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...